Our research indicates GLP1s could reduce mortality in the US by up to 6% by 2045, signalling a potential shift after years of slowing life expectancy gains linked to rising obesity and metabolic ill health
Many women report feeling queasy immediately before or during a hot flash
The result could further be an indication of a substantial and rising off-label prescribing of GLP-1 RAs, something which aligns with previous indications of an increasing off-label prescribing and misuse of GLP-1 RAs [28,29,30,31, 60], together with a media picture of substantial misuse which has been reported in recent years [23, 26, 27, 34, 36, 68]
An accelerated or priority-review pathway could theoretically compress timelines, but current trial completion and submission schedules make that outcome improbable before year-end
Edfalk, S., Steneberg, P